KCR Expands in UK & Germany and Moves on to France
KCR has opened new offices in London and Berlin, and is now turning its attention to France.
KCR, the CRO operating in 18 countries in Europe as well as the US, has opened new offices in London and Berlin, and is now turning its attention to France.
“I am very excited seeing KCR strengthening its visibility across Western Europe, particularly in the UK and Germany, where we have already been enjoying partnerships with locally based or represented companies,” says Mike Jagielski, CEO of KCR. “Having our own entities registered in these countries will make our collaboration even stronger. It will also equip KCR with local law benefits and make our business cooperation easier. The next country we will aim for is France.”
KCR has operated in Central and Eastern Europe and the Commonwealth of Independent States since 1997. Having a local team in each of the offices gives the company insight into local regulations, and has also helped to build extensive relationships with key opinion leaders and principal investigators, according to the CRO.
KCR offers three types of professional contract research services: clinical development services, functional service provision and post-marketing clinical services, in a wide spectrum of therapeutic areas.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.
